Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window of Opportunity Trial of Fenofibrate in Cervical Neoplasia and Cancer
NCT06191133Phase 1Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fenofibrate in cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC) (2 arms). Primary endpoints: Change in p53 levels at 6 weeks and Change in tumor metabolic status at 6 weeks. Started Nov 2024; status: recruiting.
02
Drugs
fenofibrate
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06191133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191133.